Shailender Bhatia

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Systemic therapy for metastatic melanoma in 2012: dawn of a new era
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
    J Natl Compr Canc Netw 10:403-12. 2012
  2. doi Temsirolimus in patients with advanced renal cell carcinoma: an overview
    Shailender Bhatia
    Division of Medical Oncology, Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Adv Ther 26:55-67. 2009
  3. doi Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report
    Shailender Bhatia
    Department of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    J Immunother 32:203-5. 2009
  4. pmc Treatment of metastatic melanoma: an overview
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    Oncology (Williston Park) 23:488-96. 2009
  5. pmc Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations
    Jayasri G Iyer
    Dermatology Division, Department of Medicine, University of Washington, Seattle, Washington
    J Am Acad Dermatol 75:541-7. 2016
  6. pmc Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma
    Astrid Blom
    Department of Medicine Dermatology, University of Washington, Seattle, Washington
    J Am Acad Dermatol 70:449-55. 2014
  7. pmc Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109
    J Exp Med 213:1133-9. 2016
  8. pmc Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
    Shailender Bhatia
    Medical Oncology, University of Washington, Seattle, WA, USA
    PLoS ONE 7:e48787. 2012
  9. pmc Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma
    Natalie J Miller
    Departments of Medicine Dermatology, Pathology, University of Washington, 850 Republican Street, Seattle, WA 98109, USA
    Curr Treat Options Oncol 14:249-63. 2013
  10. doi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008

Collaborators

Detail Information

Publications22

  1. ncbi Systemic therapy for metastatic melanoma in 2012: dawn of a new era
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA
    J Natl Compr Canc Netw 10:403-12. 2012
    ..This article reviews both the current systemic treatment options for metastatic melanoma and promising investigational approaches...
  2. doi Temsirolimus in patients with advanced renal cell carcinoma: an overview
    Shailender Bhatia
    Division of Medical Oncology, Department of Medicine, University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Adv Ther 26:55-67. 2009
    ..The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed...
  3. doi Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report
    Shailender Bhatia
    Department of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    J Immunother 32:203-5. 2009
    ..We discuss the pathophysiology and suggest careful monitoring of patients for development of this complication from ipilimumab therapy...
  4. pmc Treatment of metastatic melanoma: an overview
    Shailender Bhatia
    Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    Oncology (Williston Park) 23:488-96. 2009
    ..In this article, we review the treatments for metastatic melanoma including promising investigational approaches...
  5. pmc Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations
    Jayasri G Iyer
    Dermatology Division, Department of Medicine, University of Washington, Seattle, Washington
    J Am Acad Dermatol 75:541-7. 2016
    ..Paraneoplastic syndromes (PNS) are commonly associated with neuroendocrine cancers, such as small cell lung cancer...
  6. pmc Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma
    Astrid Blom
    Department of Medicine Dermatology, University of Washington, Seattle, Washington
    J Am Acad Dermatol 70:449-55. 2014
    ..Quantitation of circulating tumor cells (CTCs) has utility in managing breast, colon, and prostate carcinomas...
  7. pmc Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109
    J Exp Med 213:1133-9. 2016
    ..demonstrate that the combination of adoptive cellular therapy with CTLA4 blockade induces long-term remission in a melanoma patient resistant to both modalities administered serially and individually. ..
  8. pmc Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512
    Shailender Bhatia
    Medical Oncology, University of Washington, Seattle, WA, USA
    PLoS ONE 7:e48787. 2012
    ..This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with carboplatin and paclitaxel (CP) in metastatic uveal melanoma...
  9. pmc Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma
    Natalie J Miller
    Departments of Medicine Dermatology, Pathology, University of Washington, 850 Republican Street, Seattle, WA 98109, USA
    Curr Treat Options Oncol 14:249-63. 2013
    ..Due to their encouraging efficacy, low toxicity, and lack of immune suppression, these therapies may offer viable alternatives to traditional cytotoxic chemotherapy...
  10. doi Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    John A Thompson
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Mailstop G4 830, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:2034-9. 2008
    ....
  11. pmc Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
    Jayasri G Iyer
    Department of Medicine Dermatology, University of Washington, Seattle, Washington
    Cancer Med 5:2294-301. 2016
    ..These results suggest rapid emergence of chemoresistance in MCC tumors, and may serve as a useful comparator for immunotherapies currently being explored for metastatic MCC. ..
  12. doi Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base
    Shailender Bhatia
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA SB, BES, JGI, AM, UP, DB, PN Massachusetts General Hospital, Boston, MA AJS H Lee Moffitt Cancer Center, Tampa, FL VKS The University of Texas MD Anderson Cancer Center, Houston, TX JEG
    J Natl Cancer Inst 108:. 2016
    ..We performed a retrospective analysis of MCC cases from the National Cancer Data Base (NCDB) to assess whether adjuvant therapy was associated with differences in survival...
  13. pmc Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA, USA
    Cancer Immunol Res 2:27-36. 2014
    ..The combination of local and systemic immune stimulatory therapies was well-tolerated and may be a promising approach to overcome immune evasion in virus-driven cancers. ..
  14. doi Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
    Kelly G Paulson
    Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington
    Cancer . 2016
    ..Antibodies to MCPyV oncoprotein (T-antigens) have been correlated with MCC tumor burden. The present study assesses the clinical utility of MCPyV-oncoprotein antibody titers for MCC prognostication and surveillance...
  15. pmc Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma
    Jayasri G Iyer
    Department of Medicine Dermatology, University of Washington, Seattle, Washington
    Cancer Med 4:1161-70. 2015
    ..SFRT may also synergize with emerging systemic immune stimulants by lowering tumor burden and enhancing presentation of viral/tumor antigens...
  16. pmc Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma
    Kelly G Paulson
    Department of Medicine, Division of Dermatology, University of Washington, Seattle, Washington
    Cancer Immunol Res 2:1071-9. 2014
    ..This downregulation is reversible with any of several clinically available treatments that may thus promote the effectiveness of immune-stimulating therapies for MCC...
  17. pmc Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype
    Aude G Chapuis
    Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 109:4592-7. 2012
    ....
  18. doi Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: A survey of US-based radiation oncologists
    Yolanda D Tseng
    a Department of Radiation Oncology, University of Washington, Seattle, WA YDT, SA, JJL, UP Department of Medicine Medical Oncology, University of Washington, Seattle, WA SB Division of Dermatology, University of Washington, Seattle, WA
    Expert Rev Anticancer Ther . 2017
    ..It is unclear which subgroups of Merkel cell carcinoma (MCC) patients benefit the most from radiation. We surveyed radiation oncologists (RO) that regularly see and treat MCC to understand how they approach the treatment of early-stage MCC...
  19. doi Fast neutron radiotherapy for primary mucosal melanomas of the head and neck
    Jay J Liao
    University of Washington, Department of Radiation Oncology, Seattle, Washington
    Head Neck 36:1162-7. 2014
    ..Given their radioresistance, high linear energy transfer radiotherapy with neutrons may improve local control...
  20. pmc Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage
    Kelly G Paulson
    Division of Dermatology, Department of Internal Medicine, University of Washington, Seattle, Washington 98109, USA
    J Invest Dermatol 133:642-6. 2013
    ..It may be appropriate to follow these higher-risk individuals more closely, and, when clinically feasible, there may be a benefit of diminishing iatrogenic systemic immune suppression...
  21. pmc Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer
    Shailender Bhatia
    Departments of Medicine Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 98109, USA
    Curr Oncol Rep 13:488-97. 2011
    ..Here we review recent discoveries in MCC with a special focus on the pathogenic role of Merkel cell polyomavirus and the immunobiology of this virus-associated disease...
  22. pmc A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Shailender Bhatia
    Department of Medicine Medical Oncology, University of Washington Medical Center Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Ave W, G4 830, Seattle, WA, 98109 1023, USA
    Invest New Drugs 34:439-49. 2016
    ..5 months). Conclusions Pevonedistat was generally well tolerated at the MTD. Anticipated pharmacodynamic effects of NAE inhibition were observed with single-agent pevonedistat in peripheral blood and tumor tissue. ..